Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) surged to a new all-time high on Tuesday following positive phase 3 results for its sHTG drug candidate, Olezarsen. The stock saw a 34.84% increase, reaching $57.49. The studies showed a 72% reduction in blood fat and an 85% decrease in pancreas attacks among 1,100 patients.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced that Olezarsen successfully reduced blood fat by up to 72% and pancreas attacks by 85% in its phase 3 studies for severe hypertriglyceridemia. These groundbreaking results could potentially change the sHTG treatment landscape, according to SVP Sam Tsimikas.

The success of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) with Olezarsen highlights its potential as an investment. However, some AI stocks may offer higher returns with less risk. For information on a cheap AI stock poised for growth, read the free report on the best short-term AI stock.

Read more at Yahoo Finance: Ionis Pharma (IONS) Touches New High on Promising Olezarsen Results